Danko Martincic, MD
Hematology & Oncology · Post Falls, IDNPI 1124071592
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $823,971 of the $1,117,254 with a category attached, or 73.7%. 60 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 37.5% of the total. Among hematology & oncology clinicians in ID with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,424 payments — averaging $784.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$419K
- AstraZeneca$231K
- Daiichi Sankyo Inc.$131K
- Seagen Inc.$65K
- Regeneron Healthcare Solutions, Inc.$44K
- Pfizer$42K
- plus $185K from 54 others
Across 339 payments — averaging $6893.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$1M
- Merck$728K
- G1 Therapeutics, Inc.$198K
- AbbVie$148K
- Regeneron$74K
- GSK$39K
- plus $137K from 9 others
What the payments were for
- Consulting fees$158,32014%
- Speaking & faculty fees$823,97174%
- Travel & lodging$101,5759%
- Food & beverage$32,5843%
- Education$8030%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,117,254 in reported general payments places this provider in the 95th percentile of 34 hematology & oncology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 37 | $537,422 |
| RevlimidLenalidomide | 37 | $408,820 |
| PomalystPomalidomide | 20 | $360,039 |
| NubeqaDarolutamide | 20 | $253,275 |
| Lenalidomide | 18 | $164,604 |
| VenclextaVenetoclax | 12 | $114,951 |
| EliquisApixaban | 26 | $18,547 |
| Abiraterone Acetate | 26 | $15,665 |
| Fondaparinux Sodium | 12 | $9,682 |
| XareltoRivaroxaban | 16 | $8,489 |
| Fentanyl | 16 | $1,415 |
| Ondansetron OdtOndansetron | 26 | $1,291 |
| Anagrelide Hcl | 15 | $787 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 36 | $746 |
| Dexamethasone | 19 | $657 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Incyte CorporationJakafi | $45 | $537,42237 claims |
| Bristol Myers SquibbRevlimid | $36,363 | $408,82037 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $418,620 | $360,03920 claims |
| BayerNubeqa | $223 | $253,27520 claims |
| AbbVieVenclexta | $2,336 | $114,95112 claims |
| PfizerEliquis | $42,070 | $18,54726 claims |
| Johnson & JohnsonXarelto | $2,474 | $8,48916 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 34 hematology & oncology providers in Idaho.
Other hematology & oncology in Post Falls
- Jeffrey AllenPost Falls$3K
- Kevin MulveyPost Falls$483
- Bobby ChawlaCaldwell$1M
- Christian ShullIdaho Falls$150K
- Dane DicksonRexburg$21K
- Ian QureshiNampa$18K
- Nathan AdamsIdaho Falls$16K
- Andrew KominskyCoeur D Alene$13K
- David BartelsCoeur D Alene$11K
- Maria Cervantes FullmerIdaho Falls$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.